Quantcast
3 Reasons To Own Johnson & Johnson But Buy These 2 Faster-Growing High-Yield Blue-Chips Today

3 Reasons To Own Johnson & Johnson But Buy These 2 Faster-Growing High-Yield Blue-Chips Today

Posted On October 6, 2021 3:52 am
By:

High-yield blue-chips can help you sleep well at night during market downturns, such as the 10% to 20% correction that might be coming in by October 18th.

That’s when the US is currently scheduled to default on its debts for the first time in history, which Moody’s and virtually all economists think would trigger a horrific recession.

Johnson & Johnson with its recession-resistant business model and AAA credit rating is as close to a risk-free dividend stock as exists.

However, JNJ is merely a “wonderful company at a fair price” while these two faster-growing and higher-yielding blue-chips are wonderful companies at attractive valuations.

These two healthcare legends offer higher, safe yield than JNJ, and faster growth forecasts, resulting in superior long-term income and wealth compounding potential. You can’t go wrong owning or buying any of them, but for fresh savings today, these two pharma giants make better alternatives for income investors.

Continue Reading Here

About author

Dividend Sensei

I'm an Army veteran and former energy dividend writer for The Motley Fool. I'm a proud co-founder of Wide Moat Research, Dividend Kings, and the Intelligent Dividend Investor. My work can be found on Seeking Alpha, Dividend Kings, iREIT, and the Intelligent Dividend Investor. My goal is to help all people learn how to harness the awesome power of dividend growth investing to achieve their financial dreams and enrich their lives. With 24 years of investing experience, I've learned what works and more importantly, what doesn't, when it comes to building long-term wealth and income streams and achieving long-term financial goals.

Related Articles

Leave a reply

Your email address will not be published. Required fields are marked *